Walters MC, Tisdale JF, Mapara MY, Krishnamurti L, Kwiatkowski JL, Aygun B, Kasow KA, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher ME, Zhang X, Ho PR, Thompson AA, Kanter J. Sustained improvements in patient-reported quality of life up to 24 months post-treatment with LentiGlobin for sickle cell disease (bb1111) gene therapy. Presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 11, 2021. Atlanta, Georgia. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):7. doi: 10.1182/blood-2021-146905
Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang ML, Romaguera JE, Kaye JA. Overall survival, adverse events, and economic burden in Medicare-insured patients with mantle cell lymphoma receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):63. doi: 10.1182/blood-2019-122841
Goyal RK, Nagar SP, Kabadi SM, Davis KL, Le H, Kaye JA. Overall survival, adverse events, and economic burden in Medicare patients with chronic lymphocytic leukemia receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement 1):796. doi: 10.1182/blood-2019-122842
Casulo C, Byrtek M, Dawson K, Zhou X, Farber CM, Flowers CR. Early relapse of follicular lymphoma after R-CHOP uniquely defines patients at high risk for death: an analysis from the National LymphoCare Study. Presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2013. New Orleans, LA. [abstract] Blood. 2013 Nov; 122(21):510. doi: 10.1182/blood.V122.21.510.510
Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA. Clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia: evidence from U.S. hospitals, 2007-2010. Presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):239. doi: 10.1182/blood.V120.21.239.239
Sinha R, Byrtek M, DeJoubner NJ, Nooka AK, Taylor M, Cerhan JR, Ziemiecki RM. Examining the outcomes of watchful waiting (WW) among US patients with advanced stage follicular lymphoma (FL). Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):775. doi: 10.1182/blood.V118.21.775.775
Nastoupil L, Sinha R, Byrtek M, Taylor M, Cerhan JR, Friedberg J, Ziemiecki RM. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States. Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Jan; 118(21):97. doi: 10.1182/blood.V118.21.97.97